ABBOTT LABORATORIES (ABT) Form 8-K — Oct 21, 2026
Abbott reported third-quarter 2026 sales of $13.013 billion, up 14.5% reported and 7.0% on a comparable basis, with adjusted diluted EPS of $1.42 versus $1.30 a year ago. Growth was broad-based, with double-digit comparable growth in Cancer Diagnostics and Electrophysiology, and was boosted by the March 2026 acquisition of Exact Sciences. GAAP results were much weaker: net earnings fell 44.1% to $920 million and GAAP diluted EPS dropped to $0.53 from $0.94, weighed down by roughly $670 million of legal settlements for the Gill case and necrotizing enterocolitis (NEC) claims, $841 million of intangible amortization, and sharply higher net interest expense following the Exact Sciences deal.
Key figures
- Eps
- 0.53
- Revenue
- 13013000000
- Guidance
- Full-year 2026 comparable sales growth of approximately 6.0%; full-year adjusted diluted EPS of $5.50-$5.55 (midpoint reaffirmed, range tightened); Q4 2026 adjusted diluted EPS of $1.62-$1.67.
- Net Income
- 920000000
- Revenue Yoy
- 14.5%
- Net sales 3q25
- $11,369 million
- Adjusted eps yoy
- 9.2%
- Net earnings yoy
- -44.1%
- Quarterly dividend
- $0.63 per share
- Nutrition sales 3q26
- $2,262 million
- Diagnostics sales 3q26
- $3,305 million (+46.7% reported, +6.4% comparable)
- Adjusted diluted eps 3q25
- $1.30
- Adjusted diluted eps 3q26
- $1.42
- Medical devices sales 3q26
- $5,826 million
- Comparable sales growth 3q26
- 7.0%
- Established pharma sales 3q26
- $1,614 million
- Consecutive quarterly dividends
- 411
- Legal settlements specified 3q26
- ~$670 million (Gill case and NEC claims)
- Specified items net after tax 3q26
- $1.557 billion ($0.89 per share)
- Consecutive years dividend increases
- 54
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.